tradingkey.logo

Illumina Inc

ILMN
134.780USD
+4.270+3.27%
Close 12/19, 16:00ETQuotes delayed by 15 min
20.62BMarket Cap
30.06P/E TTM

Illumina Inc

134.780
+4.270+3.27%

More Details of Illumina Inc Company

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Illumina Inc Info

Ticker SymbolILMN
Company nameIllumina Inc
IPO dateJun 28, 2000
CEOThaysen (Jacob)
Number of employees8970
Security typeOrdinary Share
Fiscal year-endJun 28
Address5200 Illumina Way
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92122
Phone18582024500
Websitehttps://www.illumina.com
Ticker SymbolILMN
IPO dateJun 28, 2000
CEOThaysen (Jacob)

Company Executives of Illumina Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
23.64K
-5.22%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
+20.59%
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
21.03K
+21.92%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
+23.09%
Ms. Patricia (Pat) Leckman
Ms. Patricia (Pat) Leckman
Chief People Officer
Chief People Officer
18.95K
-1.54%
Mr. Scott Davies
Mr. Scott Davies
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
18.93K
+58.70%
Dr. Gary S. Guthart, Ph.D.
Dr. Gary S. Guthart, Ph.D.
Independent Director
Independent Director
16.43K
+29.88%
Dr. Steven (Steve) Barnard, Ph.D.
Dr. Steven (Steve) Barnard, Ph.D.
Chief Technology Officer
Chief Technology Officer
16.32K
-3.06%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Director
Independent Director
15.19K
+21.71%
Ms. Susan E. (Sue) Siegel
Ms. Susan E. (Sue) Siegel
Independent Director
Independent Director
14.46K
+35.38%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jacob Thaysen, Ph.D.
Mr. Jacob Thaysen, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
23.64K
-5.22%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
22.14K
+20.59%
Dr. Frances H. Arnold, Ph.D.
Dr. Frances H. Arnold, Ph.D.
Independent Director
Independent Director
21.03K
+21.92%
Mr. Philip W. (Phil) Schiller
Mr. Philip W. (Phil) Schiller
Independent Director
Independent Director
20.15K
+23.09%
Ms. Patricia (Pat) Leckman
Ms. Patricia (Pat) Leckman
Chief People Officer
Chief People Officer
18.95K
-1.54%
Mr. Scott Davies
Mr. Scott Davies
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
18.93K
+58.70%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Consumables
811.00M
76.58%
Services and Other revenue
147.00M
13.88%
Instruments
101.00M
9.54%
By RegionUSD
Name
Revenue
Proportion
Americas
586.00M
55.34%
Europe
310.00M
29.27%
Asia, Middle East, and Africa
100.00M
9.44%
Greater China
63.00M
5.95%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
811.00M
76.58%
Services and Other revenue
147.00M
13.88%
Instruments
101.00M
9.54%

Shareholding Stats

Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
13.07%
The Vanguard Group, Inc.
9.52%
BlackRock Institutional Trust Company, N.A.
8.60%
State Street Investment Management (US)
3.93%
Sessa Capital
3.07%
Other
61.81%
Shareholders
Shareholders
Proportion
Capital World Investors
13.07%
The Vanguard Group, Inc.
9.52%
BlackRock Institutional Trust Company, N.A.
8.60%
State Street Investment Management (US)
3.93%
Sessa Capital
3.07%
Other
61.81%
Shareholder Types
Shareholders
Proportion
Investment Advisor
58.08%
Investment Advisor/Hedge Fund
26.57%
Hedge Fund
12.40%
Pension Fund
3.24%
Bank and Trust
2.02%
Research Firm
2.00%
Sovereign Wealth Fund
0.27%
Family Office
0.25%
Individual Investor
0.19%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1888
158.57M
103.78%
-23.77M
2025Q2
1978
167.87M
109.04%
-18.11M
2025Q1
2072
170.79M
107.89%
-16.32M
2024Q4
2074
166.23M
104.94%
-15.71M
2024Q3
2038
151.41M
95.06%
-11.30M
2024Q2
2033
149.41M
93.80%
-18.06M
2024Q1
2096
153.02M
96.09%
-8.97M
2023Q4
2134
150.48M
94.76%
-5.28M
2023Q3
2162
152.18M
96.14%
-14.52M
2023Q2
2203
154.10M
97.47%
-5.40M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
16.65M
10.83%
-2.25M
-11.93%
Jun 30, 2025
The Vanguard Group, Inc.
15.08M
9.81%
-1.22M
-7.49%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
13.61M
8.86%
-401.16K
-2.86%
Jun 30, 2025
State Street Investment Management (US)
5.62M
3.65%
-234.60K
-4.01%
Jun 30, 2025
Sessa Capital
4.72M
3.07%
+4.72M
--
Jun 30, 2025
Loomis, Sayles & Company, L.P.
4.23M
2.75%
+78.32K
+1.89%
Jun 30, 2025
WCM Investment Management
4.43M
2.88%
+247.46K
+5.92%
Jun 30, 2025
Corvex Management LP
3.83M
2.49%
--
--
Jun 30, 2025
AQR Capital Management, LLC
3.30M
2.14%
+1.17M
+55.35%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.87M
1.87%
+21.34K
+0.75%
Jun 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
6.09%
Global X Genomics & Biotechnology ETF
5.58%
First Trust Nasdaq Lux Digi Health Solutions ETF
4.96%
First Trust NYSE Arca Biotechnology Index Fund
4.42%
ARK Genomic Revolution ETF
4.38%
VanEck Biotech ETF
3.09%
Alger Russell Innovation ETF
2.61%
First Trust NASDAQ Pharmaceuticals ETF
2.39%
iShares Health Innovation Active ETF
2.29%
First Trust Health Care Alphadex Fund
2.27%
View more
Invesco Biotechnology & Genome ETF
Proportion6.09%
Global X Genomics & Biotechnology ETF
Proportion5.58%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion4.96%
First Trust NYSE Arca Biotechnology Index Fund
Proportion4.42%
ARK Genomic Revolution ETF
Proportion4.38%
VanEck Biotech ETF
Proportion3.09%
Alger Russell Innovation ETF
Proportion2.61%
First Trust NASDAQ Pharmaceuticals ETF
Proportion2.39%
iShares Health Innovation Active ETF
Proportion2.29%
First Trust Health Care Alphadex Fund
Proportion2.27%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data

FAQs

Who are the top five shareholders of Illumina Inc?

The top five shareholders of Illumina Inc are:
Capital World Investors holds 16.65M shares, accounting for 10.83% of the total shares.
The Vanguard Group, Inc. holds 15.08M shares, accounting for 9.81% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 13.61M shares, accounting for 8.86% of the total shares.
State Street Investment Management (US) holds 5.62M shares, accounting for 3.65% of the total shares.
Sessa Capital holds 4.72M shares, accounting for 3.07% of the total shares.

What are the top three shareholder types of Illumina Inc?

The top three shareholder types of Illumina Inc are:
Capital World Investors
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.

How many institutions hold shares of Illumina Inc (ILMN)?

As of 2025Q3, 1888 institutions hold shares of Illumina Inc, with a combined market value of approximately 158.57M, accounting for 103.78% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -5.27%.

What is the biggest source of revenue for Illumina Inc?

In FY2025Q2, the Consumables business generated the highest revenue for Illumina Inc, amounting to 811.00M and accounting for 76.58% of total revenue.
KeyAI